Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Recombinant chimeric protein with strong anti-tumor activity. Cintredekin besudotox consists of the pleiotropic immunomodulatory cytokine interleukin 13 (IL13), which is linked to the mutant form of Pseudomonas exotoxin A. The drug targets and kills tumor cells that express IL13 receptor (IL13R). IL13 is partially attached to IL13R on the tumor cell membrane, promoting the entry of exotoxin. Exotoxin induces caspase-mediated apoptosis of tumor cells in part through mechanisms involving mitochondrial damage. It also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor 2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.